Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 177

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation

Open access
Piccini, Jonathan P., Hellkamp, Anne S., Washam, Jeffrey B., Becker, Richard C., Breithardt, Günter, Berkowitz, Scott D., Halperin, Jonathan L., Hankey, Graeme J., Hacke, Werner, Mahaffey, Kenneth W., Nessel, Christopher C., Singer, Daniel E., Fox, Keith A.A., Patel, Manesh R. · 2016 · Circulation

Abstract

Background—: Patients with atrial fibrillation (AF) often take multiple medications. Methods and Results—: We examined characteristics and compared adjusted outcomes between rivaroxaban and warfarin according to number of concomitant baseline medications and the presence of combined cytochrome P450 3A4 and P-glycoprotein inhibitors in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study. At baseline, 5101 patients (36%) were on 0 to 4 medications, 7298 (51%) were on 5 to 9, and 1865 (13%) were on ≥10. Although polypharmacy was not associated with higher risk of stroke or non–central nervous system embolism (adjusted hazard ratio, 1.02 for ≥10 versus 0–4 medications; 95% confidence interval, 0.76–1.38), it was associated with higher risks of the combined end point of stroke, non–central nervous system embolism, vascular death, or myocardial infarction (adjusted hazard ratio, 1.41 for ≥10 versus 0–4 medications; 95% confidence interval, 1.18–1.68) and nonmajor clinically relevant or major bleeding (adjusted hazard ratio, 1.47 for ≥10 versus 0–4 medications; 95% confidence interval, 1.31–1.65). There was no significant difference in primary efficacy (adjusted interaction P =0.99) or safety outcomes (adjusted interaction P =0.87) between treatment groups by number of medications. Patients treated with 0 to 4 medications had lower rates of major bleeding with rivaroxaban (adjusted hazard ratio, 0.71; 95% confidence interval, 0.52–0.95; interaction P =0.0074). There was no evidence of differential outcomes in those treated with ≥1 combined cytochrome P450 3A4 and P-glycoprotein inhibitors. Conclusions—: In a population of patients with atrial fibrillation, two thirds were on ≥5 medications. Increasing medication use was associated with higher risk of bleeding but not stroke. Rivaroxaban was tolerated across complex patients on multiple medications. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00403767.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.115.018544

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 177

Metadata

Authors
Piccini, J. P., Hellkamp, A. S., Washam, J. B., Becker, R. C., Breithardt, G., Berkowitz, S. D., Halperin, J. L., Hankey, G. J., Hacke, W., Mahaffey, K. W., Nessel, C. C., Singer, D. E., Fox, K. A. A., & Patel, M. R.
Venue
Circulation
Published
2016-01-26
Volume
133
Issue
4
Pages
352-360
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2219896033
Cited by
177
References
2
FWCI
10.48
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. https://app.cochat.ai/papers/10.1161/circulationaha.115.018544
The paper
Piccini, J. P., Hellkamp, A. S., Washam, J. B., Becker, R. C., Breithardt, G., Berkowitz, S. D., Halperin, J. L., Hankey, G. J., Hacke, W., Mahaffey, K. W., Nessel, C. C., Singer, D. E., Fox, K. A. A., & Patel, M. R. (2016). Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Circulation. https://doi.org/10.1161/circulationaha.115.018544

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.